Published in Vaccine Weekly, April 19th, 2006
Dawson James Securities, a healthcare and biotechnology investment banking firm, acted as the placement agent.
Viragen intends to use the proceeds raised from this offering to continue funding its drug research and development plans, regulatory strategies and proceed with the international marketing of Multiferon in its approved territories, including Sweden where the drug was recently...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly